Search

Search Constraints

You searched for: Author/Creator Samson, Pearl

Search Results

1. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Issue 1 (January 2022)

2. Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment. (13th June 2019)

3. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3–36 months with HIV infection. (15th May 2017)

4. Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. (1st August 2019)

5. Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. (15th March 2022)

6. Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age. (15th March 2022)

7. Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents. Issue 2 (February 2015)

8. Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. Issue 2 (February 2015)

9. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. (25th May 2020)

10. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Issue 6 (June 2015)